The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
NICE is your answer @Franky. These machines are cost effective in that the cost of running 100s tests works out cheaper (and better for patients/families) than having a deaf baby to manage. Trusts aren't heartless and the Drs and nurses on these neonatal units will push for the tests. Don't forget the NHS asked GDR to develop the test. These see a need. The machines themselves aren't expensive or the tests especially when you look at the savings.
@Ghia it's an observational ie non interventional trial using Standard of care. Alas SNG001 isn't standard of care therefore it won't be used. Unless the situation changes whilst the trial is underway...
@dsaf nothing by Tom W himself on his twitter page or his website. Please share something from him
@dsaf nothing on Tom's site pertaining to ODX since March this year. Can you share the link to this rumour from him? Thanks
@captain again please explain your interest in the share that you're not invested in? Why do you post so much? Maybe you could speak to someone regarding your borderline personality disorder https://www.nhs.uk/mental-health/conditions/borderline-personality-disorder/overview/
Genuinely worried for you. I'm a bag holder in this share I admit. You're not even a share holder and you're here.
@captain in that case bless you. Maybe you could try the job board or something else to fill your time.
@captain speaking of which repeating a million times a day. Please tell us why someone with no investment in ODX or indeed interest in any other share (going by history) spend so much time posting here? You must have better things to do? Possibly not?
@Tommy from this feed https://twitter.com/boulware_dr/status/1557486955818094593?s=20&t=bNlOknYyTwgybmwFJUEoKw
An ID dr shared a pic of a hard copy of NEJM dated 18th Aug. Mary Aurelien posted underneath Activ 2 or 6? We are due Activ publication at some point. Could be something or nothing.
I admit I've topped up a fair bit today. The 190k one just now is mine. The food test is going great guns and they are looking to expand the test to include microbiome which is a massive growth area. Fun fact, there are more bacterial cells in your body than your own cells.
Up 18% company is undervalued. The loss making part has been sold. There is cash to expand the food intolerance business which is making money already. Finncap have odx at 12p. Good return from here.
We're number 3 on the charts today. We have had great news. The company has removed the final loss making millstone from its neck. Food intolerance is going great guns. We have as much money in the bank as our mcap so already undervalued. Finncap have put the target at 12p. That's decent from this level.
Latest target is 12p. From these levels is a great opportunity!
This is great news. We've sold the loss making part of the business with money that should help us expand our food until test into the biggest market in the world. Onwards and upwards.
Our cash matches our mcap seriously undervalued.
It's very good news. Small company. Orders already. It will snowball. They are presenting at the biggest oncology conference in the world. More oncologists and pharma are attending this than any other. Importantly its in America as well where the product is launched.
@captain what's your opinion on the chunky 100ks blue trades going through this morning. Fair few bright and early.
@aether they took bloods at day 0 determine immunogenicity in SPRINTER (its right above device training for patients in their protocol) . They also took plasma and serum in Activ 2 (presumably to determine auto antibodies and interferon expression). This isn't their first rodeo. They know more than most the difference in expression in patients.